Skin disorder therapeutic - NanoVation Therapeutics
Latest Information Update: 24 Apr 2026
At a glance
- Originator NanoVation Therapeutics
- Class Skin disorder therapies; Small interfering RNA
- Mechanism of Action RNA interference
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes - Skin disorders
Highest Development Phases
- Preclinical Skin disorders
Most Recent Events
- 16 Feb 2026 Skin disorder therapeutic - NanoVation Therapeutics is available for licensing as of 12 Feb 2026. https://nanovationtx.com/partnership-to-enable-gene-therapies/
- 12 Feb 2026 Preclinical trials in Skin disorders in Canada (IV) prior to February 2026 (NanoVation Therapeutics pipeline, February 2026)